Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABP-700 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ABP-700 30 μg/kg/min | EXPERIMENTAL | Starting intravenous (IV) infusion rate of 50 micrograms per kilogram per minute (μg/kg/min) for 5 minutes, followed by 30 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions. |
| ABP-700 40 μg/kg/min | EXPERIMENTAL | Starting IV infusion rate of 70 μg/kg/min for 3 minutes, followed by 40 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions. |
| ABP-700 45 μg/kg/min | EXPERIMENTAL | Starting IV infusion rate of 80 μg/kg/min for 3 minutes, followed by 45 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions. |
| Name | Type | Description |
|---|---|---|
| ABP-700 | DRUG | - |
Inclusion Criteria: * Participant must be male or female 18 to 75 years of age, inclusive * Participant must give written informed consent before initiation of any study-related procedures * Participant is scheduled to undergo elective colonoscopy * Body Mass Index (BMI) 18.0 to 29.0 kilogram per m...
ABP-700 is an investigational small molecule being developed for procedural sedation in adult patients undergoing colonoscopy. It was studied in a Phase 2 trial evaluating three dosing regimens for sedation during this procedure. It is not approved for any indication and remains in clinical development.
ABP-700 targets GABA-A receptor subunits, specifically GABRA1, GABRB2, GABRG2, GABRB3, GABRA4, and GABRG3. It acts as an agonist at these targets, meaning it activates the receptor complex. This mechanism is intended to produce sedation for procedural use.
ABP-700 is being developed by Novartis AG, which trades under the ticker NVS. The company sponsored the clinical trial investigating the drug for procedural sedation in colonoscopy.
ABP-700 is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA or any regulatory agency for commercial use.
ABP-700 has been studied in one completed Phase 2 trial, NCT02800590, titled a study to investigate the safety and efficacy of three dosing regimens of ABP-700 for procedural sedation in adult participants undergoing colonoscopy. The trial enrolled 150 participants in the Netherlands and was randomized and controlled.